Phase I/II Study of Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

Trial Profile

Phase I/II Study of Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Vorinostat (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jan 2017 Status changed from active, no longer recruiting to discontinued.
    • 22 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
    • 17 Jan 2014 Planned end date changed from 1 Sep 2013 to 1 Sep 2015 as per According to ClinicalTrials.gov, the estimated completion date is July 2018 and the final data collection date for primary outcome is July 2017 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top